Instructions for Authors

Scope
Cancer Epidemiology, Biomarkers & Prevention publishes original research on cancer causation and prevention in humans. The following topics are of special interest: descriptive, analytical, biochemical and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention.

Particular attention will be given to the identification of factors associated with various aspects of the carcinogenic process, including genetic susceptibility, host factors, infectious agents, chemical and physical carcinogens, environmental factors, dietary components and behavioral factors such as tobacco use and sun exposure.

Besides welcoming manuscripts that address individual subjects in any of the three disciplines, the Editors encourage the submission of manuscripts with an interdisciplinary approach.

Contents
- Original research articles
- Invited editorials
- Selected review articles
- AACC and ASPO news

Editorial Policy
When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the publisher and copyright owner of the journal, prior to publication. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of the Declaration is available from the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France.

Journal policy requires that authors, reviewers, and Associate Editors reveal to the Editor-in-Chief any relationships that they believe could be construed as causing a conflict of interest with regard to the manuscript submitted for review.

Manuscript Submission
Mail manuscripts directly to Dr. Pelayo Correa, Editor-in-Chief. Submit four original sets (not photocopies) of illustrations along with four copies of the manuscript. Illustrations will be returned to the author if the paper is not accepted for publication. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. FAX transmission and overnight delivery service will be used to expedite review and publication.

Publication Fees
A page charge of $35 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no other source of grant or other support exists, the author(s) may apply to Dr. Margaret Foul, Director of Publications, AACC Publications Department (see end of page for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Format
Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:
1. Title page, including title, authors, and affiliations
2. A running title of fewer than 50 characters
3. Text, arranged in this order: Abstract (not more than 250 words), Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References
4. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals.
5. Tables, on pages separate from the text, with descriptive titles and/or legends.
6. Figure legends, on pages separate from the text. Define all symbols and include staining for halftones, where applicable.

References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission.

Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

Sample references:

Illustrations
Provide four original sets of illustrations (whether line-cut drawings or halftones). Label each figure in pencil on the reverse side with the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on illustrations should not be smaller than 6-point or larger than 12-point type. All illustrations will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with the greatest fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. In 1996, the cost of color reproduction charged to authors will be $975 per color figure. Submit color illustrations on flexible backing.

Proofs
Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors’ corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive changes in proof.

Typesetting Manuscripts from Computer Disks
Cancer Epidemiology, Biomarkers & Prevention welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission and a form which must be completed and returned with your disk to the AACC Publications Department within 48 hours of notification of acceptance. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

For More Information:
Dr. Pelayo Correa, Editor-in-Chief, CECP. Department of Pathology, Louisiana State University Medical Center, 1901 Perdido Street, New Orleans, LA 70112-1393. Telephones: (504)529-2848; (504)568-6035; FAX: (504)529-2849.

Or:
BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR) is a scientific society consisting of laboratory and clinical cancer researchers. It was founded in 1907 and its purposes are "to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world." Members of the AACR enjoy the following benefits:

1. the opportunity to subscribe to the journals Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at the reduced member rate.
   - Cancer Research publishes over 7,000 pages per year of timely, significant research. With over 40,000 citations to its articles per year, it rates as the most highly cited journal in the cancer field.
   - Cell Growth & Differentiation, a journal of the molecular biology of cancer, has established a tradition of rapid publication with an average review time of 2-3 weeks and an average of 10 weeks between acceptance and publication.
   - Cancer Epidemiology, Biomarkers & Prevention has already established itself as a leading journal with a wholly unique scope, providing a common forum for three scientific areas that are rapidly expanding our knowledge of cancer causation and prevention in humans.
   - Clinical Cancer Research, the AACR's newest journal, began publication in 1995. Focusing on innovative translational studies, it publishes original laboratory and clinical research on the molecular characterization, prevention, diagnosis, and therapy of human cancer.

2. the privilege of sponsoring a paper for possible presentation at the AACR Annual Meeting;

3. an advance copy of the Program and, if one has been purchased, Proceedings pertaining to each Annual Meeting;

4. reduced registration rates at Annual Meetings;

5. priority notice of and reduced registration rates for small, focused meetings in the AACR's Special Conferences in Cancer Research;

6. opportunities for participation in the AACR's meetings with other scientific societies around the world;

7. subscriptions to future AACR journals at reduced member rates;

8. the receipt of AACR newsletters and meeting announcements;

9. early notification of and reduced rates for participation in the Employment Register;

10. an up-to-date Membership Directory;

11. participation in Summer Workshops that foster networking opportunities and science education for young investigators;

12. the benefits of the AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings; and

13. many more ongoing benefits.
BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 10,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American Association for Cancer Research pertaining to each annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
5. reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of thousands of researchers in the cancer field;
10. the professional benefits of the AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. participation in Summer Workshops that foster networking opportunities and science education for young investigators; and
12. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application in AACR Office</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. –OR– The nominator may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in item 3 above from a secondor who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The secondor may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1996 annual dues for active members are $160, $95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full.

Corresponding members are required to pay dues ($80 in 1996) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE:__________________________ DATE OF BIRTH:__________

LAST FIRST M.I.

PRESENT POSITION/TITLE:__________________________

INSTITUTIONAL AFFILIATION:__________________________

INSTITUTIONAL ADDRESS:__________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER:______________________________ FAX NUMBER:______________________________

E-MAIL NUMBER (CARRIER):__________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

____Biochemistry and Biophysics  _______Biostatistics  _______Carcinogenesis

____Cellular Biology and Genetics  _______Clinical Investigations  _______Endocrinology

____Epidemiology  _______Immunology  _______Molecular Biology and Genetics

____Preclinical Pharmacology and Experimental Therapeutics  _______Virology  _______Other:__________

(Please specify)

ACADEMIC DEGREES (Including where and when granted)

__________________________________________________________

__________________________________________________________

EXPRESSIVE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

__________________________________________________________

__________________________________________________________

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

__________________________________________________________

__________________________________________________________

__________________________________________________________

CANDIDATE NOMINATED BY*:__________________________

(Please print)

CANDIDATE SECONDED BY*:__________________________

(Please print)

CANDIDATE IS APPLYING FOR (Check one): □ ACTIVE □ CORRESPONDING MEMBERSHIP

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? _____years

Will the candidate make a long-term contribution to cancer research? _____Yes _____No

Does the candidate's research adhere to accepted ethical standards? _____Yes _____No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator* __________________________ Date __________________________

Signature of seconder* __________________________ Date __________________________

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a paper for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students.);
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
6. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
7. reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the $35 or $45 dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1995 and 1996 have been set at $35 per year for residents of the Americas and $45 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1995 for the forthcoming annual meeting must have paid dues for 1995. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1995 may retain associate membership until December 31, 1999. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: ____________________________ DATE OF BIRTH: ________________

LAST FIRST M.I.

INSTITUTIONAL AFFILIATION: ______________________________________________________

INSTITUTIONAL ADDRESS: _______________________________________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ____________________________ FAX NUMBER: ______________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one): _______________________________________________________________________

Graduate Student Medical Student
Physician in Training Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

__Biochemistry and Biophysics__ Biostatistics__ Carcinogenesis
__Cellular Biology and Genetics__ Clinical Investigations__ Endocrinology
__Epidemiology__ Immunology__ Molecular Biology and Genetics
__Preclinical Pharmacology and Experimental Therapeutics__ Virology__ Other: ____________________________

(please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

__________________________________________________________________________________

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

__________________________________________________________________________________

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

__________________________________________________________________________________

CANDIDATE NOMINATED BY: _______________________________________________________

(Please type or print name of AACR member* in good standing.)

SIGNATURES
I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: __________________________________________ Date: ______________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: __________________________________________ Date: ______________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:
The enclosed dues payment should be applied to the □ current □ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)
87th AACR Annual Meeting
Preliminary Program
(All events take place in the Washington Convention Center, unless otherwise indicated.
Names of session chairpersons are underlined.)

SATURDAY, APRIL 20, 1996

11:00 a.m.-8:00 p.m. Registration

12:00 noon-6:30 p.m. Educational Sessions (Sessions are two hours in length. Exact schedule to be announced.)

ED1 Human Pharmacogenetics: Molecular Mechanisms and Clinical Relevance in Cancer Treatment, William E. Evans, Denis M. Grant, Robert B. Diasio


ED3 The Cell Cycle: Michael B. Kastan, William G. Kaelin, Jr., Chi Van Dang

ED4 Beyond the Human Genome Project: Technical Aspects of Genomic Characterization and Its Application to Cancer Research, Glen A. Evans

ED5 Combinatorial Library Methods for Basic Research and Drug Discovery, Sydney F. Salmon, Kit S. Lam, George Smith, Victor Krchnak


2:00 p.m.-6:00 p.m. Methods Workshops (Separate registration required)

WK1 Quantitative Biology and Pharmacodynamics, Robert C. Jackson, Robert L. Dedrick, Mark J. Ratain, William R. Greco


6:30 p.m.-8:30 p.m. Women in Cancer Research Guest Lecture and Reception, Washington, DC Renaissance Hotel

8:00 p.m.-10:00 p.m. Opening Mixer, Washington, DC Renaissance Hotel

8:00 a.m.-12:00 noon Poster Sessions

MB2 Viral Oncogenesis
MB3 Transcription Factors
MB4 Lung and Skin Cancer
ET2 Pharmacokinetics and Toxicology
ET3 Reversal of P-Glycoprotein Resistance by Small Molecules
ET4 Gene Therapy I - Tumor Directed Therapies
ET5 Genetic Determinants of Chemosensitivity
IM2 Cytokines and Tumor Immunity I
EN2 Prostate Cancer I
CI2 Supportive Care and Tumor Biology
CG2 Chemical Carcinogenesis
CG3 Genetic and Cytogenetic Alterations in Human Tumor Cells
BL2 Invasion and Motility
BL3 Genetic Changes and Alter Gene Expression During Tumor Progression
EP1 Genetic Epidemiology - Prevention and Susceptibility
EP2 Retinoids, Antioxidants, and NSAIDS

8:15 a.m.-11:45 a.m. Minisymposia

CI1 Leukemia and Lymphoma
CG1 Biomarkers of Chemical Exposure
ET1 DNA Topoisomerase I and Camptothecins
BL1 Mechanisms of Apoptosis

8:15 a.m.-11:30 a.m. Plenary Session

The Progress and Promise of Cancer Research: A Celebration of the Twentieth Anniversary of the National Cancer Act, Joseph R. Bertino, Harold E. Varmus, Arnold J. Levine, Susan Band Horwitz, Lloyd J. Old, Paul Talalay, James F. Holland

11:45 a.m.-12:45 p.m. 35th Clowes Award Lecture

Robert A. Weinberg, Control of Proliferation by the Cell Cycle Clock

12:30 p.m.-5:00 p.m. Commercial Exhibit Show

1:00 p.m.-2:00 p.m. Controversy Session 1

Are Antioxidants Useful in Cancer Prevention?, Waun Ki Hong, Frank L. Meyshens, Jr., E. Robert Greenberg

1:00 p.m.-2:00 p.m. Controversy Session 2

Have Preclinical Models In Studies of Drug Resistance Provided Accurate Predictions for Clinicians?, Bruce A. Chabner, Susan E. Bates, Herbert M. Pinedo

1:00 p.m.-5:00 p.m. Poster Discussion Sessions

BL4 Genes Involved in Invasion and Metastasis
ET7 DNA Repair and Its Inhibition
CG4 Oxygen Radicals

1:00 p.m.-5:00 p.m. Poster Discussion Sessions

MB6 Signal Transduction
MB7 Gene Regulation in Breast Cancer
MB8 Gene Regulation
ET8 Expression of Drug Resistance Genes in Human Tumors
ET9 P-Glycoprotein, MRP, and Other Mechanisms of Multidrug Resistance
ET10 rasraf Directed Therapy
ET11 Pyrimidine Antimetabolites
IM3 Cytokines and Tumor Immunity II
EN3 Growth Factors and Cell Surface Receptors
CI4 Phase II/III Studies
CG5 Animal Models
BL5 Growth Factors and Cytokines
BL6 Biological Aspects of Drug Resistance

SUNDAY, APRIL 21, 1996

7:00 a.m.-4:00 p.m. Registration

7:00 a.m.-8:00 a.m. Sunrise Sessions

SUN1 Diane F. Birt: Mechanisms of Dietary Prevention of Cancer
SUN2 William S. Dalton: Challenges in Bone Marrow Transplantation
SUN3 Ronald B. Herberman: Natural Killer Cells
SUN4 Rakesh K. Jain: Tumor Pathophysiology: Role in Delivery of Molecules, Particles, and Cells
SUN5 Lovell A. Jones: Estrogens and Breast Cancer
SUN6 Stanley J. Korshmeier: Apoptosis: Regulation and Oncogenesis
SUN7 Funmi I. Olopade: Chromosomal Deletions and Cancer: Recent Advances in Mapping Techniques

7:00 a.m.-8:00 a.m. State Legislative Committees Meeting

7:00 a.m.-8:00 a.m. State Legislative Committees Meeting

8:00 a.m.-12:00 noon Poster Discussion Sessions

IM1 Antigens, Vaccines, and Monoclonal Antibodies
EN1 Breast Cancer I
MB1 Gene Expression in Breast Cancer I

1:45 p.m.-5:15 p.m.  Minisymposia
C13  Clinical Pharmacology I
ET6  New Drugs I
MB1  Telomerase I

2:15 p.m.-5:15 p.m.  Symposia
S1  Tumor Suppressor Genes, Bert Vogelstein, Yosef Shiloh, Todd Waldman, Alexander Kamb, Allan Bradley, Richard D. Klausner
S2  Ovarian Cancer: From the Laboratory to the Clinic, Robert E. Ozols, Thomas C. Hamilton, Donald M. Black, E.G. Elisabeth de Vries, David T. Curiel
S4  Monoclonal Antibodies: Clinical Effectiveness, Ellen S. Vitetta, Mark Slwikowski, Pamela A. Trail, Dana C. Matthews

5:30 p.m.-6:30 p.m.  Joseph H. Burchenal AACR Clinical Research Award Lecture

6:30 p.m.-9:00 p.m.  Minority Issues Committee Symposium. Reflections from Scientists: Their Pathways to Success, Marian Johnson-Thompson, Tracie Bunton, Cesar Calderon, Jerrel Yakel, Ricardo J. Parker, Harold Amos. Washington, DC Renaissance Hotel

8:00 p.m.-10:30 p.m.  Annual Reception. Grand Hyatt Washington Hotel

MONDAY, APRIL 22, 1996

7:00 a.m.-4:00 p.m.  Registration

7:00 a.m.-8:00 a.m.  Sunrise Sessions
SUN8  Peggy J. Farnham: Nuclear Oncogenes: Effects on Cell Cycle Regulation and Neoplastic Transformation
SUN9  John G. Gibben: Quantitative PCR as a Tool to Detect Minimal Residual Disease in Leukemia and Lymphoma
SUN10  Stephen S. Hecht: Chemoprevention of Cancers Associated with Tobacco Use
SUN11  V. Craig Jordan: Antiestrogens
SUN12  Philip Livingston: Specific Immunotheperapy of Melanoma
SUN13  John A. McLachlan: Environmental Carcinogens: Their Impact in Cancer
SUN14  Daniel Medina: Multistage Mammary Carcinogenesis

7:00 a.m.-8:00 p.m.  WICR Networking Session. Washington, DC Renaissance Hotel

8:00 a.m.-11:00 a.m.  Symposia
S6  Steroid Hormones: Breast and Prostate Cancer, Myles A. Brown, Benita S. Katerman, Donald P. McDonnell, Norman M. Greenberg, Roger L. Miesfeld
S7  Matrix Metalloproteinases and Their Inhibitors, Lynn M. Matsunaga, Ruth J. Muschel, Motohara Seiki, Yves DeClerck, Peter Brown

8:00 a.m.-12:00 noon  Poster Discussion Sessions
BL8  Apoptosis
MB9  DNA Repair
ET13  Biology of MRP

8:00 a.m.-12:00 noon  Poster Sessions
BL9  Tumor Vasculature and Angiogenesis
BL10  Differentiation and Growth Inhibition
BL11  Regulation and Characterization of Cell Cycle Genes
IM5  Immunobiology
EN4  Nuclear Receptors and Signal Transduction
CI5  Clinical Pharmacology II
CG6  Molecular Responses to DNA Damage
CG7  Cell Culture and Animal Models
EP5  Cancer Biomarkers
ET14  Novel Topoisomerase Inhibitors
ET15  Kinase Directed Therapies
ET16  Novel Antitumor Agents I
ET17  Novel Antitumor Agents II
MB10  p53
MB11  Oncogenes I
MB12  Gene Expression I

8:15 a.m.-11:45 a.m.  Minisymposia
EP4  Mechanisms of Chemoprevention
IM4  Tumor Antigens and Effector Cell Response
ET12  Novel Drug Resistance Mechanisms
RR2  Radiation, Apoptosis, and the Cell Cycle

10:00 a.m.-4:00 p.m.  Commercial Exhibit Show

11:30 a.m.-12:45 p.m.  Presidential Address

1:00 p.m.-2:00 p.m.  Fifth American Cancer Society Award Lecture
Lee W. Wattenberg, Prevention of Cancer: The Role of Chemoprevention for the General Population and for Individuals at High Risk Due to Genetic Defects or Other Factors

1:00 p.m.-5:00 p.m.  Poster Discussion Sessions
CG8  Carcinogen Metabolism in Animals and Humans
BL13  Molecular Effectors of Tumor Progression
ET18  Antifolate and Thymidylate Synthase Inhibitors

1:00 p.m.-5:00 p.m.  Poster Sessions
BL14  Antiinvasion or Metastasis Strategies
BL15  Behavior of Naturally Occurring Tumors and Model Systems
IM6  Immunomodulation
IM7  Modulation of T Cell Function
IM8  Modulation of Macrophage and NK/LAK Cell Function
CI7  Clinical Pharmacology - Pharmacokinetics
CG9  Metabolism and Activation of Carcinogens in Animal Models
CG10  Tumor Promotion/Progression
EN6  Breast Cancer II
ET19  Alkylation Agents and Platinum Analogs I

Boldface Codes: ES=Education Session, SS=Symposia, WK=Methods Workshop, SUN=Meet-the-Expert Sunrise Session, BL=Tumor Biology, CG=Carcinogenesis, CI=Clinical Investigations, EN=Endocrinology, EF=Epidemiology and Prevention, ET=Experimental Therapeutics, IM=Immunology/Biological Therapy, MB=Molecular Biology/Biochemistry, RR=Radiobiology/Radiation Oncology.
TUESDAY, APRIL 23, 1996

7:00 a.m.-4:00 p.m. Registration
7:00 a.m.-8:00 a.m. Sunrise Sessions
SUN15 Robert L. Comis: Lung Cancer: A Primer
SUN16 Jerry D. Glickson: NMR As a Prognosticator of Tumor Therapeutic Response
SUN17 Susan Jaken: Protein Kinase C in Carcinogenesis
SUN18 Jay A. Levy: Immunological Features of AIDS Pathogenesis
SUN19 Yves G. Pommier: DNA Topoisomerases and Their Inhibitors
SUN20 Barrett J. Rollins: Chemokines and Leukocyte-specific Chemotactic and Activating Factors
SUN21 Stephen E. Sallan: Childhood Leukemias: The Latest in Treatment
7:00 a.m.-8:00 a.m. NIH Grants Session. Grand Hyatt Washington Hotel
8:00 a.m.-11:00 a.m. Symposium
S14 Endogenous DNA Damage: Detection and Biological Significance. John M. Essigmann, Leona D. Samson, B. Singer, Lawrence J. Marnett, Lawrence A. Loeb
S16 Aberrant Transcription Factors and Malignancy. Lorraine J. Gudas, A. Thomas Lowy, Anne Dejean, Christopher T. Denny, Terry H. Rabbitts
S17 Thymidylate Synthase and Its Inhibitors. Frank Maley, Carmen Allegra, Gary K. Smith, William R. Montfort, Bruce J. Dolnick
8:00 a.m.-12:00 noon Poster Discussion Sessions
BL17 Signal Transduction I
CI8 Markers of Response and Predictors of Outcome in Solid Tumors
ET24 New Approaches to Drug Discovery and Selective Therapeutics
8:00 a.m.-12:00 noon Poster Sessions
ET25 Purine and Pyrimidine Antagonists
ET26 Combination Chemotherapy
ET27 Tubulin Inhibitors
ET28 Chemoprevention Therapeutics and Other Antitumor Agents
MB18 Telomerase II
MB19 Gene Amplification and Chromosome Mapping
MB20 Oncogenes II
EP7 Mechanisms of Chemoprevention by Endogenous and Dietary Factors
IM9 Gene Therapy
EN7 Hormonal Carcinogenesis and Hormonal Control of Cell Growth and Death
BL18 Apoptosis - Molecular Mechanisms I
BL19 Kinetics, Models (Cell Growth and Death)
CG11 Metabolism and Activation of Carcinogens in Humans
CG12 Genetic Susceptibility and Premalignant Lesions in Humans
CJ9 Phase I and II Clinical Trials
CI10 Clinical Biology of Solid Tumors
8:15 a.m.-11:45 a.m. Minisymposia
EP6 Genetic Epidemiology: Genetic Susceptibility and Gene-environmental Interaction
ET23 Resistance to Platinum Drugs
MB17 Tumor Suppressor Genes I
BL16 Host Effects on Tumor Cells: Angiogenesis
11:00 a.m.-5:00 p.m. Commercial Exhibit Show
11:45 a.m.-12:45 p.m. 20th Rosenthal Award Lecture
James O. Armitage. The Place of Bone Marrow Transplantation in the Management of Patients with Lymphoma
1:00 p.m.-2:00 p.m. Late-breaking Research Session
1:00 p.m.-5:00 p.m. Poster Discussion Sessions
CI11 Biology of Breast Cancer
ET30 P-Glycoprotein: Structure/Function Studies
MB21 Prostate Cancer
1:00 p.m.-5:00 p.m. Poster Sessions
ET31 Ribozyme and Antisense Gene Therapy Strategies
ET32 Chimeric Toxins and Enzyme-derived Therapies
ET33 Antifolates
ET34 Lipid Ethers and Other Lipid Antitumor Agents
MB22 Gene Expression in Breast Cancer II
MB23 DNA Repair and Methylation
MB24 Tumor Suppressor Genes II
EP8 Genetic Susceptibility/Gene-environmental Interactions/Other Epidemiological Studies
IM11 Melanoma Associated Antigens and Effector Cell Response
IM12 Antigens, Vaccines, and Effector Cell Responses
BL21 Proteases: Their Role in Metastasis and Invasion
BL22 Adhesion
BL23 Effect of Carbohydrates on Metastasis and Invasion, Adhesion and Proteases
CG14 Altered Gene Expression in Carcinogenesis
RR3 p53/Radioimmunotherapy/Phototherapy
CI12 Clinical Tumor Biology I
1:45 p.m.-5:15 p.m. Minisymposia
IM10 Cytokines and Effector Cells
ET29 Epidermal Growth Factor Receptor Directed Therapeutics
CG13 Carcinogen-DNA Adducts: Influence on Transcription and Replication
BL20 Invasion and Metastasis
WEDNESDAY, APRIL 24, 1996

7:00 a.m.-2:00 p.m. Registration

7:00 a.m.-8:00 a.m. Sunrise Sessions
SUN22 Ernest C. Borden: Interferons in Cancer
SUN23 Richard A. Heyman: Transcription Factors As Therapeutic Targets

8:00 a.m.-11:00 a.m. Symposium
S23 Drug Metabolizing Enzymes in Cancer Prevention and Therapy. Cecil B. Pickett, F. Peter Guengerich, Frank J. Gonzalez, Chung S. Yang

8:00 a.m.-12:00 noon Poster Discussion Sessions
EP9 Mutation Epidemiology and Biomarkers of Environmental Exposure
ET36 Therapy Directed Apoptosis
IM13 Cytokines and Tumor Immunity III

8:00 a.m.-12:00 noon Poster Sessions
EN8 Hormone Action, Hormone Synthesis, Metabolism, and Inhibitors
BL24 Apoptosis - Molecular Mechanisms II
BL25 Regulation of Cell Cycle Genes by Endogenous and Exogenous Factors
BL26 Extracellular Matrix, Signaling, and Adhesion
CG16 DNA Adducts
CG17 Exposure Biomarkers
CI14 Clinical Tumor Biology II
EP10 Effects of Chemopreventive Agents on Carcinogen Metabolism and DNA Adducts

IM14 Monoclonal Antibodies: Immunoconjugates and Immunotherapy
MB26 Techniques in Molecular Biology
MB27 Enzymes and Isoenzymes
MB28 Gene Expression in Ovarian Cancer
ET37 Taxol
ET38 Gene Therapy II - Gene Transfer, Cell Cycle, and Other Studies
ET39 Pharmacodynamics
ET40 Glutathione and Other Drug Resistance Mechanisms

8:15 a.m.-11:45 a.m. Minisymposia
CI13 Phase I Trials
CG15 Signal Transduction in Tumor Progression
ET35 Human Gene Therapy: Early Trial Results and Promising New Leads
MB25 Microsatellite Instability

11:45 a.m.-12:45 p.m. 15th Cain Award Lecture
Kurt W. Kohn, Beyond DNA Crosslinking

1:00 p.m.-2:00 p.m. Controversy Session 4
Is p53/BR Important for Therapeutic Outcome?, William F. Benedict, Carlos Cordon-Cardo, David Sidransky

1:00 p.m.-5:00 p.m. Poster Sessions
EN10 Gynecological, Lung, and Genitourinary Cancers
RR4 Animal and Patient Studies with Radiation/Drug-Radiation Studies
BL28 Apoptosis - Clinical Implications
BL29 Signal Transduction II
CG18 Mutagenesis and Repair
CG19 Growth Factors and Signaling in Carcinogenesis
CI16 Clinical Tumor Biology III
IM15 Monoclonal Antibodies: Immunoconjugates and Immunotherapy
MB30 Tumor Suppressor Genes III
MB31 Tumor Suppressor Genes IV
MB32 Gene Regulation and Expression
ET43 Regulation of P-Glycoprotein Expression
ET44 New Drugs II
ET45 Tumor Models and Methods of Drug Delivery
ET46 Liposomes and Drug Delivery Formulations
ET47 Experimental Drug Resistance

1:45 p.m.-5:15 p.m. Minisymposia
BL27 Novel Signaling Pathways and Crosstalk
CI15 Predictors of Response and Prognosis Markers in Solid Tumors
EN9 Prostate Cancer II
ET41 Alkylating Agents and Platinum Analogs II

2:15 p.m.-5:15 p.m. Symposia
S26 Genetic Predisposition to Cancer, Mark H. Skolnick, Francis S. Collins, Richard D. Kolodner, William B. Isaacs, Sean Tavtigian

ADVANCE REGISTRATION FORM

AMERICAN ASSOCIATION FOR CANCER RESEARCH
87TH ANNUAL MEETING - WASHINGTON, DC - April 20-24, 1996

Return to
American Association for Cancer Research • Public Ledger Building, Suite 816
150 S. Independence Mall West • Philadelphia, PA 19106-3483 • FAX: 215-440-7228

DEADLINES:
• March 1, 1996 for reduced rates and to ensure receipt of meeting materials by mail in late March or early April
• March 25, 1996 for all registration by mail (Registration forms received after this date will not be accepted. Registration will be conducted at the Washington Convention Center from April 20-24.)
• April 17, 1996 to cancel registration and receive refund less cancellation fee ($35)

(Please print)

NAME: ___________________________ Last First/Middle Initial AACR Member Number

TITLE: ___________________________ ADDRESS: ___________________________

Institution

Street, Building, or Post Office Box

City State or Province Zip/Postal Code Country (if not U.S.)

TELEPHONE NO.: ___________________ FAX NO.: ___________________

☐ Check this box if you have a physical disability and have special requirements for transportation, hotel accommodations, or other facilities in connection with the meeting. A member of the Association staff will contact you.

WHAT IS YOUR PRIMARY FIELD OF RESEARCH (Please check only one):
☐ Biochemistry and Biophysics ☐ Carcinogenesis ☐ Cellular Biology & Genetics ☐ Clinical Investigations
☐ Endocrinology ☐ Epidemiology ☐ Experimental Therapeutics ☐ Immunology ☐ Molecular Biology & Genetics
☐ Prevention ☐ Radiobiology/Radiation Oncology ☐ Virology ☐ Other (please specify): ___________________________

ARE YOU THE PRESENTER OF AN ABSTRACT SUBMITTED FOR THE 1996 AACR MEETING? ☐ Yes ☐ No

ON WHICH DAYS WILL YOU ATTEND THE 1996 AACR ANNUAL MEETING?
☐ Saturday, April 20 ☐ Sunday, April 21 ☐ Monday, April 22 ☐ Tuesday, April 23 ☐ Wednesday, April 24

PAYMENT OF REGISTRATION

Fees may be paid by check or with a MasterCard, VISA, American Express, or Eurocard account. All payments must be made in U.S. currency, and all checks must be drawn on a U.S. bank. Payment must accompany this form; purchase orders will not be accepted as payment.

<table>
<thead>
<tr>
<th></th>
<th>On or Before March 1</th>
<th>After March 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active/Corresponding Member Rate</td>
<td>$135</td>
<td>$170</td>
</tr>
<tr>
<td>Nonmember Rate</td>
<td>$270</td>
<td>$340</td>
</tr>
<tr>
<td>(includes copy of AACR Proceedings)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emeritus Member Rate</td>
<td>$ 50</td>
<td>$ 50</td>
</tr>
<tr>
<td>Associate Member Ratec</td>
<td>$ 75</td>
<td>$ 85</td>
</tr>
<tr>
<td>Predoctoral Student Ratec</td>
<td>$ 60</td>
<td>$ 70</td>
</tr>
<tr>
<td>Honorary Member Rate</td>
<td>$ 0</td>
<td>$ 0</td>
</tr>
<tr>
<td>AACR Proceedingsd</td>
<td>$ 35 Members</td>
<td>$ 35 Members</td>
</tr>
<tr>
<td></td>
<td>$ 45 Nonmembers</td>
<td>$ 45 Nonmembers</td>
</tr>
<tr>
<td>Optional Overseas Surcharged</td>
<td>$ 25</td>
<td>N.A.</td>
</tr>
<tr>
<td>Proceedings on CD-ROM</td>
<td>$ 35 Members</td>
<td>$ 35 Members</td>
</tr>
<tr>
<td></td>
<td>$ 45 Nonmembers</td>
<td>$ 45 Nonmembers</td>
</tr>
<tr>
<td>Methods Workshop Registration</td>
<td>$ 50 Members</td>
<td>$ 50 Nonmembers</td>
</tr>
<tr>
<td></td>
<td>$ 75 Nonmembers</td>
<td>$ 75 Nonmembers</td>
</tr>
<tr>
<td>TOTAL ENCLOSED OR CHARGED</td>
<td>$</td>
<td>$</td>
</tr>
</tbody>
</table>

METHOD OF PAYMENT

☐ Check payable to AACR, Inc. in U.S. currency, drawn on a U.S. bank

Person/Institution Issuing Check

Check No.: ___________________________

☐ MasterCard ☐ VISA ☐ American Express ☐ Eurocard

Card Number ___________________________

Expiration Date ___________________________

Signature ___________________________

*An application for Associate Membership may accompany this form, but these should be submitted well before the March 1 deadline, as review of the Associate Membership application may delay registration.

*Students must enclose a statement, signed by the registrar, dean, or department head of their university or college on official letterhead, confirming their status. Postdoctoral fellows or physicians in training do not qualify for the student registration rate.

*AACR members with paid-up subscriptions to an AACR journal and registrants who pay the nonmember fee receive the Proceedings automatically. If these members or nonmembers check this box and pay the fee, they will receive an additional copy of the Proceedings.

*Optional payment for registrants outside of the U.S. and Canada only. Registrants paying this surcharge will receive meeting publications via airmail—printed matter before the annual meeting. This service not available after March 1.

AACR members in good standing will receive copies of the Program and Proceedings prior to the meeting. Nonmember and student registrants who meet the March 1 deadline will also receive the Program and if they have purchased it the Proceedings prior to the meeting. Nonmembers and students who do not meet the deadline must pick up publications at the meeting site.

REFUND POLICY

Refunds on registration fees will be granted on written request received in the AACR office by April 17, 1996. Requests received after this date will not be honored. Receipts and badges (if they have been mailed) must be returned to the AACR Office with the refund request. A cancellation fee of $35 will be deducted from all refunds to cover administrative costs.

(This form may be reproduced.)
One hour has been set aside for the presentation of about 4 definitive reports of highly significant and timely findings in the field. Criteria for the selection of these presentations and instructions for submission of abstracts are as follows:

**INSTRUCTIONS FOR SUBMISSION OF LATE-BREAKING ABSTRACTS**

1. The work to be presented must be of major novelty and significance, *e.g.*, the characterization of a new gene in familial cancer, and should not have been previously published in a peer-reviewed scientific journal or presented at a national meeting.

2. The abstract must be sponsored by an AACR member in good standing (dues paid for 1996).

3. Each member in good standing may sponsor only **one** abstract for this session whether or not he or she sponsored an abstract last December for the regular annual meeting program. If an associate member is the **sponsor**, the abstract must also be **endorsed** by an active or corresponding member in good standing. In this case, the **endorser** does **not** forfeit the opportunity to **sponsor** a late-breaking abstract.

4. Abstracts must be typed on **one** side of **one** sheet of white paper.

5. All text on the page must fit within an area 6 1/2" wide and 9" high (16.5 cm X 22.9 cm) with margins of at least 1" (2.5 cm) on the top, bottom, and sides of the page.

6. Each abstract must be accompanied by a covering letter from the sponsor explaining why the work is novel and significant enough to be considered for this late-breaking research session and certifying that the findings became available **after** the annual meeting abstract deadline of December 1, 1995. This letter must contain the sponsor's complete mailing address, FAX number, and Email address (if available) so that we can communicate the scheduling decision of the Program Committee.

7. Abstracts and covering letters must be received in the AACR Office by 5:00 p.m. Eastern Time on **March 15, 1996**. FAX transmissions are **not** acceptable. Carrying envelopes should be clearly marked "Late-Breaking Abstract," and should be addressed to American Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. If you wish to receive acknowledgment of receipt of your abstract, enclose a self-addressed post card with appropriate postage affixed. Accepted abstracts will not be published since they will be received after the *Proceedings of the American Association for Cancer Research* has been printed; however, they will be distributed at the session in Washington.

8. A special subcommittee of the Program Committee appointed by President Joseph R. Bertino will select the papers to be presented. Presenters of accepted papers will be notified via FAX no later than **March 29, 1996**.
CARCINOGENESIS FROM ENVIRONMENTAL POLLUTION: ASSESSMENT OF HUMAN RISK AND STRATEGIES FOR PREVENTION

Joint Meeting Organized by the American Association for Cancer Research (AACR) and the International Agency for Research on Cancer (IARC)

With the Collaboration of the Hungarian Cancer Society

October 6-9, 1996
Hotel Gellért
Budapest, Hungary

CONFERENCE CHAIRPERSONS
Frederica Perera / New York, USA
Paul Kleihues / Lyon, France

PROGRAM COMMITTEE

Hans-Olov Adami / Uppsala, Sweden
J. Carl Barrett / Research Triangle Park, USA
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Mieczyslaw R. Chorzy / Gliwice, Poland
Joseph F. Fraumeni, Jr. / Bethesda, USA
Waun Ki Hong / Houston, USA
Margaret L. Kripe / Houston, USA
Kenneth Olden / Research Triangle Park, USA
Alán Pintér / Budapest, Hungary
Manfred F. Rajewsky / Essen, Germany
David Zaridze / Moscow, Russia

SCIENTIFIC PROGRAM

Keynote Address
Curtis C. Harris / Bethesda, USA

Cancer Incidence and Etiology
Witold A. Zatorowski / Warsaw, Poland
Frederica Perera / New York, USA
J. Carl Barrett / Research Triangle Park, USA
Helmut Bartsch / Heidelberg, Germany

Air, Water, Food, and Soil Contamination
Rudim J. Šram / Prague, Czech Republic
Joelien Lewtas / Research Triangle Park, USA
Wieslaw Jedrychowski / Cracow, Poland
Olav Axelson / Linköping, Sweden

Ambient, Environmental, and Occupation Exposure and Cancer Risk
Mieczyslaw R. Chorzy / Gliwice, Poland
Alán Pintér / Budapest, Hungary
Kimmo Peltonen / Helsinki, Finland
Monica C. Hollstein / Heidelberg, Germany
Kari Hemminki / Stockholm, Sweden

Tobacco
Ivan Plesko / Bratislava, Slovakia
Barbara S. Hulka / Chapel Hill, USA
Paolo L. Vineis / Turin, Italy
Stephen S. Hecht / Valhalla, USA
Krystyna Frenkel / New York, USA
Bernadette Schoket / Budapest, Hungary

Strategies for Prevention
Waun Ki Hong / Houston, USA
I. Bernard Weinstein / New York, USA
Anna Tompa / Budapest, Hungary

Roundtable Discussion
Paul Kleihues / Lyon, France
Hans-Olov Adami / Uppsala, Sweden
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Andrew E. Czeizel / Budapest, Hungary
Terri Damstra / Research Triangle Park, USA
Edith Olah / Budapest, Hungary
Kenneth Olden / Research Triangle Park, USA
Manfred F. Rajewsky / Essen, Germany
William A. Suk / Research Triangle Park, USA
David Zaridze / Moscow, Russia

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)
Email: aacr@aol.com
FEBRUARY 19-25, 1996
*Cancer Susceptibility Genes and Molecular Carcinogenesis*
Chairpersons: Curtis C. Harris, Bethesda, MD; Allan Balmain, Glasgow, Scotland; Kenneth Olden, Research Triangle Park, NC
Keystone Resort, Keystone, CO

MARCH 1-5, 1996
*Proteases and Protease Inhibitors*
Chairpersons: Lynn M. Matrisian, Nashville, TN; Bonnie F. Sloane, Detroit, MI
Marriott's Bay Point Resort, Panama City Beach, FL

APRIL 20-24, 1996
87th Annual Meeting
Chairperson: Lorraine J. Gudas, New York, NY
Washington D.C. Convention Center, Washington, D.C.
Abstract Deadline: December 1, 1995

JUNE 8-12, 1996
*Inducible Genomic Responses*
Chairpersons: William T. Beck, Memphis, TN; John A. Hickman, Manchester, England; Richard I. Morimoto, Evanston, IL
Skamania Lodge, Stevenson (Columbia River Gorge), WA

OCTOBER 2-6, 1996
*Novel Approaches in Blood and Marrow Transplantation*
Second Annual Meeting of the American Society for Blood and Marrow Transplantation
Chairpersons: O. Michael Colvin, Durham, NC; Bruce R. Blazar, Minneapolis, MN
Hotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996
*Carcinogenesis from Environmental Pollution: Assessment of Human Risks and Strategies for Prevention*
Joint Meeting with International Agency for Research on Cancer
Chairpersons: Frederica Perera, New York, NY; Paul Kleihues, Lyon, France
Hotel Gellért, Budapest, Hungary

OCTOBER 19-23, 1996
*Programmed Cell Death*
Chairperson: Stanley J. Korsmeyer, St. Louis, MO
The Sagamore, Bolton Landing (Lake George), NY

JANUARY 10-14, 1997
*Basic and Clinical Aspects of Lymphoma*
Joint Meeting with the American Society of Clinical Oncology
Chairpersons: Joseph R. Bertino, New York, NY; James O. Armitage, Omaha, NE
Stouffer Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

JANUARY 17-21, 1997
*Disrupted Transcription Factors in Cancer*
Chairpersons: Peter K. Vogt, La Jolla, CA; Frank J. Rauscher III, Philadelphia, PA
Hotel Del Coronado, San Diego, CA

FEBRUARY 13-16, 1997
*Growth Factors, Signaling, and Cancer*
Joint Meeting with Lorne Cancer Congress
Chairpersons: Antony Burgess, Parkville, Victoria, Australia; Robert S. Coffey, Nashville, TN; Ashley R. Dunn, Parkville, Victoria, Australia; Webster K. Cavenee, La Jolla, CA
Erskine House, Lorne, Victoria, Australia

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: aacr@aol.com
The American Association for Cancer Research Presents

Molecular Biology in Clinical Oncology: A Workshop
Supported by a Generous Grant from the National Cancer Institute

An intensive, one-week summer workshop on molecular biology designed for clinical oncologists in training or in their early academic careers.

June 28-July 4, 1996
Given Biomedical Institute
Aspen, Colorado

ORGANIZERS

STEPHEN H. FRIEND
Fred Hutchinson Cancer Research Center
Seattle, WA

L. MICHAEL GLODÉ
University of Colorado
School of Medicine
Denver, CO

JENNIFER A. PIETENPOL
Vanderbilt University
School of Medicine
Nashville, TN

• Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology. Topics include gene therapy, oncogenes and growth factors, tumor suppressor genes, molecular genetics, metastasis genes, and drug design.

• Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology.

• Category I CME credits through the University of Colorado School of Medicine.

• A workshop syllabus containing relevant published papers, references to key articles in the literature, and details on important laboratory procedures.

• Financial support for participants who are physicians in training or oncology fellows.

Faculty

LECTURES

ANDRÉ BERNARDS/ Charlestown, MA
KATHLEEN R. CHO/ Baltimore, MD
CYNTHIA A. EDWARDS/ Redwood City, CA
ROBERT N. EISENMAN/ Seattle, WA
ERIC R. FEARON/ Ann Arbor, MI
STEPHEN H. FRIEND/ Seattle, WA

LELAND H. HARTWELL/ Seattle, WA
TYLER JACKS/ Cambridge, MA
MARY-CLAIRE KING/ Seattle, WA
RICHARD D. KLAUSNER/ Bethesda, MD
MARC E. LIPPMAN/ Washington, DC
A. THOMAS LOOK/ Memphis, TN
HAROLD L. MOSES/ Nashville, TN

GARY J. NABEL/ Ann Arbor, MI
ALLEN I. OLIFF/ West Point, PA
JENNIFER A. PIETENPOL/ Nashville, TN
NADIA ROSENTHAL/ Charlestown, MA
PATRICIA S. STEEG/ Bethesda, MD
MIN WU/ Beijing, P. R. C.

Laboratory Rotations

MARK S. BOGUSKI/ Bethesda, MD. "Computer Searching in Molecular Biology."
JULIE A. CAMPAIN/ Denver, CO. "Polymerase Chain Reaction Technology."
JAMES P. HOEFFLER/ San Diego, CA. "Transfer of Nucleic Acids and Proteins."
MARILEILA V. GARCIA/ Denver, CO. "Practical Cytogenetics."
CORI GORMAN/Burlingame, CA. "Gene Expression Systems."

Application Deadline March 25, 1996

For further information, contact

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313
Email: aacr@aol.com
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PRESENTS

An Important Educational Opportunity Primarily for Predoctoral and Postdoctoral Fellows
Contemplating Careers in Basic Cancer Research

HISTOPATHOBIOLOGY OF NEOPLASIA

The Edward A. Smuckler Memorial Workshop
Supported by a Generous Grant from the National Cancer Institute

Keystone Conference Center
Keystone, Colorado
July 21 - July 28, 1996

- Intensive training in the histopathology and biology of neoplasia.
- Twenty-eight hours of hands-on laboratory exercises directed by distinguished pathologists.
- An outstanding series of lectures on rapidly developing areas of cancer research by laboratory directors and other prominent investigators.
- Extensive written course materials that will serve as valuable references in the future.
- Waiver of registration fee and partial support for students’ and fellows’ lodging and subsistence expenses during the workshop.

LABORATORY AND LECTURING FACULTY

Helen D. Feiner*, New York University School of Medicine, New York, NY Course Director
Stephen Baird, Veterans Administration Medical Center, San Diego, CA
Edward Bresnick, University of Massachusetts Medical Center, Worcester, MA
Arthur R. Brothman, University of Utah, Salt Lake City, UT
Betty DeMasters, University of Colorado School of Medicine, Denver, CO
Isaiah J. Fidler, UT M.D. Anderson Cancer Center, Houston, TX
Michael B. Kastan, Johns Hopkins University Hospital, Baltimore, MD
Mary-Claire King, University of Washington, Seattle, WA
John H. Lehman, Albany College of Medicine, Albany, NY
Michael W. Lieberman, Baylor College of Medicine, Houston, TX
Reuben Lotan, UT M.D. Anderson Cancer Center, Houston, TX
Robert Low*, University of Colorado School of Medicine, Denver, CO
Gary J. Miller*, University of Colorado School of Medicine, Denver, CO
Harold L. Moses, Vanderbilt University School of Medicine, Nashville, TN
Karl Munger, Harvard Medical School, Boston, MA
Stewart Sell, University of Texas Medical School, Houston, TX
Patricia A. Thomas, University of Iowa Hospital and Clinics, Iowa City, IA
Ann D. Thor, Northwestern University, Chicago, IL
Frederic M. Waldman*, University of California, San Francisco, CA

Additional Faculty to be Announced

*Member of the Workshop Executive Committee

APPLICATION DEADLINE: APRIL 30, 1996

Further Information: American Association for Cancer Research • Public Ledger Building 150 S. Independence Mall West • Suite 816 • Philadelphia, PA 19106-3483 Telephone: (215) 440-9300 • FAX: (215) 440-9313 • E-mail: AACR@aol.com
Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

- MacWrite
- WordPerfect (DOS, Windows, and Macintosh)
- Microsoft Word (DOS, Windows, and Macintosh)
- XyWrite (DOS and Windows)
- Ability
- Mass 11
- SoloWriter
- AmiPro
- MS Windows Write
- Sprint
- A_S-TeX
- MS Works
- Stx
- Appleworks
- MS Works WP Mac
- Symphomy
- ArborTeX
- Multimate
- TEX
- ArborText
- Multimate Advantage
- TeX78
- ClarisWorks WP
- Nibia
- CPT 8000
- Nisus (to ASCII file)
- Text EExecutive
- CTOS
- Notewriter
- Textures
- Diablo
- Obun
- Total Word
- DisplayWrite
- OfficeWriter
- Troff
- Duet
- PC Write
- TeX
- Einstein
- PFS First Choice
- Volkswriter
- Enable
- Professional Write
- VuWriter
- EXP
- Q&A Write
- Wang OIS
- Final Word
- Quark XPress
- Wang WPS
- FullWrite
- RagTime MS Works
- Wang Writer
- GemWord Plus
- (to ASCII file)
- Window Works
- IBM Writing Assistant
- Rich Text Format
- Windows Write
- Interleaf
- RSG (to ASCII file)
- WiziWord
- \LaTeX
- Signature
- Wordstar
- Latex
- SL\TeX
- Wordstar 2000
- Leading Edge
- SmartWhere
- WriteNow
- Lotus Manuscript
- SmartWrite II
- Xerox
- Lotus Write

Software packages that we are unable to translate:

- FrameMaker
- Ready, Set, Go
- PageMaker
- Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ____________________________________________________
Name of computer used (e.g., IBM/PS2): ______________________________________________
Operating system and version (e.g., DOS 3.3): _________________________________________
Word processing program and version (e.g., WordPerfect 5.0): ____________________________
[See reverse for acceptable programs.]

Manuscript number: __________________________________________________________________
First author:  Adam Smith
Corresponding author (if different from first author): _________________________________
Telephone/FAX numbers: __________________________________________________________________

This form (both sides) may be reproduced.